Anamorelin vs Ibutamoren

Head-to-head comparison of Anamorelin (Anamorelin hydrochloride (ONO-7643)) and Ibutamoren (Ibutamoren mesylate (MK-677)) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyAnamorelinIbutamoren
CategoryGrowth HormoneGrowth Hormone
Full NameAnamorelin hydrochloride (ONO-7643)Ibutamoren mesylate (MK-677)
Molecular WeightN/AN/A
Half-Lifeabout 9 hoursabout 24 hours
Amino AcidsN/AN/A
Typical Dose50 mg/day10-25 mg/day
RouteOralOral
Purity≥98%≥98%
Studies Count95180
Research StatusClinicalClinical

Anamorelin Benefits

  • stimulates appetite
  • raises IGF-1
  • may support weight gain
  • oral dosing

Ibutamoren Benefits

  • raises GH/IGF-1
  • increases appetite
  • supports lean mass retention
  • oral non-peptide secretagogue

Anamorelin Dosing

50 mg orally once daily|often studied with food or per protocol|track weight, appetite, and glucose markers

Ibutamoren Dosing

10-25 mg orally once daily|take consistently at the same time each day|monitor fasting glucose and edema in longer studies

Anamorelin Side Effects

  • hyperglycemia
  • peripheral edema
  • constipation or nausea

Ibutamoren Side Effects

  • increased appetite
  • water retention/edema
  • somnolence or lethargy

Research Overview

Anamorelin

Trials in cachexia populations showed increased appetite and modest gains in body weight and IGF-1. Regulatory progress has varied by region, but it remains a well-studied ghrelin agonist in the GH space.

Ibutamoren

Clinical studies show oral ibutamoren reliably elevates GH and IGF-1 over 24 hours with once-daily dosing. Body composition and appetite effects vary by population, and development has been limited by metabolic side effects.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

Anamorelin stacks with:

Nutritional supportResistance training

Ibutamoren stacks with:

Resistance trainingHigh-protein diet
ghrelin-agonistcachexiagh-secretagogueghrelin-receptor-agonistoral